The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.

Nine years after being diagnosed with metastatic lung cancer, Roszell Mack Jr., 87, still goes into the office every day thanks to a durable response to the immunotherapy pembrolizumab.

Bioimpedance spectroscopy (BIS) is better than a tape measure for assessing a woman’s risk for developing lymphedema.

The varying roles that signaling molecules play in progression of cancer is the focus of the Vanderbilt-Ingram Cancer Center 20th Annual Scientific Retreat when some of the nation’s top experts will speak about “Signal Transduction in Cancer Initiation, Progression and Treatment.”

Asian countries are in the early stages of a tobacco smoking epidemic with habits mirroring those of the United States from past decades, setting the stage for a spike in future deaths from smoking-related diseases.